Starpharma and Monash awarded STEM+ Business fellowships
|
Biotech news and industry publication Biotech Dispatch covered the news that Starpharma and the Monash Institute of Pharmaceutical Sciences (MIPS) were awarded $300,000 in grant funding from the SIEF STEM+ Business Fellowship Program to engage two post-doctoral Research Fellows. The funding allows both Starpharma and Monash to further advance collaborative programs utilising Starpharma’s DEP platform. To view the article, click here. |
Hope is on the way for one of the world’s most common sexual problems
Investor publication Stockhead recently covered Starpharma’s VivaGel® BV Phase 3 announcement for prevention of recurrent bacterial vaginosis (rBV). The publication noted the significant unmet patient need for BV treatments and how VivaGel® BV targets one of the most common vaginal conditions affecting women of childbearing age.
Go to article (external link)
Starpharma readies US NDA for VivaGel® on positive results in Phase 3 Bacterial vaginosis
Biotech trade publication noted Starpharma expects to file an NDA for VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) with the US FDA following the positive results of the Phase 3 trials.
Starpharma and Monash awarded STEM+ Business Fellowships
Starpharma today announced that Starpharma and Monash Institute of Pharmaceutical Sciences (MIPS) have been awarded $300,000 in grant funding from the SIEF STEM+ Business Fellowship Program to engage two post-doctoral Research Fellows.
Successful VivaGel® Phase 3 results and NDA planned for rBV
Starpharma today announced that its two phase 3 trials of VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) achieved their primary objective demonstrating statistically significant superiority compared to placebo in preventing rBV based on topline data.
Biotech clinical trials a star performer
Herald Sun covered the investor interest in Starpharma following the positive results of the company’s VivaGel® BV Phase 3 clinical trials for the prevention of recurrent bacterial vaginosis (rBV). Starpharma CEO Dr Jackie Fairley noted VivaGel® BV demonstrated sustained benefits for patients three months after their initial treatment, positioning the company to unlock a multi-million dollar global market.
Go to article (external link)
Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2017.
Shareholder Update July 2017
In this issue:
>> Starpharma sells Agrochemicals business to Agrium for $35M cash
>> DEP® irinotecan outperforms irinotecan in multiple cancer models
>> DEP® docetaxel, DEP® cabazitaxel and scale-up facilities
>> AstraZeneca pays US$2M DEP® milestone to Starpharma
>> VivaGel® BV phase 3 results timing and commercialisation
>> VivaGel® condom launched in Canada
>> Sale of Ansell's Sexual Wellness division
>> Starpharma News & Events
Download: Shareholder Update July 2017 (pdf file, 710kb)
VivaGel® BV phase 3 results timing and commercialisation
Starpharma today announced revised timing for results of its two pivotal VivaGel® BV phase 3 trials for the prevention of recurrent bacterial vaginosis – now expected to be available in late July/early August 2017.
Starpharma’s sale of its agrochemical business and technology, expands Agrium’s tech base
The sale of Starpharma’s agrochemical business was recently covered in Farm Weekly, highlighting the unique opportunity that Starpharma’s Priostar® dendrimer technology brings to the agrochemical market and the commercial value Agrium saw in the technology. In the article, Starpharma CEO Dr Jackie Fairley details the sale, including the patent transfer, total sale proceeds and the implications for the Company.